Claims

We claim:

1. A method of treating ulcers in a human which comprises administering to a human in need of treatment for ulcers, a therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof.

2. A method of treating gastroesophageal reflux disease in a human which comprises administering to a human in need of treatment for gastroesophageal reflux disease, a therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof.

3. A method of treating a condition caused by or contributed to by gastric hypersecretion in a human which comprises administering to a human in need of treatment for a condition caused by or contributed to by gastric hypersecretion, a therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof.

4. A method of treating psoriasis in a human which comprises administering to a human in need of treatment for psoriasis, a therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof.

5. The method of claim 1, wherein the rabeprazole is administered orally.

6. The method of claim 5, wherein the therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 200 mg per day.

7. The method of claim 1, wherein the rabeprazole comprises at least approximately 90% by weight *S*(-)rabeprazole and 10% or less by weight of *R*(+)rabeprazole.

8. The method of claim 7, wherein the rabeprazole comprises at least approximately 99% by weight *S*(-)rabeprazole and 1% or less by weight of *R*(+)rabeprazole..

9. The method of claim 2, wherein the rabeprazole is administered orally.

10. The method of claim 9, wherein the therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 200 mg per day.

11. The method of claim 2, wherein the rabeprazole comprises at least approximately 90% by weight *S*(-)rabeprazole and 10% or less by weight of *R*(+)rabeprazole..

12. The method of claim 3, wherein the condition caused by or contributed to by gastric hypersecretion is Zollinger-Ellison Syndrome.

13. The method of claim 3, wherein the rabeprazole is administered orally.

14. The method of claim 13, wherein the therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 200 mg per day.

15. The method of claim 3, wherein the rabeprazole comprises at least approximately 90% by weight *S*(-)rabeprazole and 10% or less by weight of *R*(+)rabeprazole..

16. The method of claim 4, wherein the rabeprazole is administered orally.

17. The method of claim 16, wherein the therapeutically effective amount of rabeprazole, the rabeprazole comprising optically pure *S*(-)rabeprazole, or a pharmaceutically acceptable salt thereof administered is from about 5 mg to about 200 mg per day.

18. The method of claim 4, wherein the rabeprazole comprises at least approximately 90% by weight *S*(-)rabeprazole and 10% or less by weight of *R*(+)rabeprazole..

19. A pharmaceutical composition comprising a therapeutically effective amount of rabeprazole, containing at least approximately 90% by weight *S*(-)rabeprazole and 10% or less by weight *R*(+)rabeprazole, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier for oral administration of the composition.

20. The pharmaceutical composition of claim 19, in the form of a tablet or capsule.